PRAX PE Ratio & Valuation, Is PRAX Overvalued

Historical Valuation

Praxis Precision Medicines Inc (PRAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8230.35 is considered Overvalued compared with the five-year average of -4.21. The fair price of Praxis Precision Medicines Inc (PRAX) is between 35.02 to 173.40 according to relative valuation method. Compared to the current price of 309.91 USD , Praxis Precision Medicines Inc By Overvalued By 78.72%.

Relative Value

Fair Zone

35.02-173.40

Current Price：309.91

78.72%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Praxis Precision Medicines Inc (PRAX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Praxis Precision Medicines Inc (PRAX) has a current Price-to-Book (P/B) ratio of 17.65. Compared to its 3-year average P/B ratio of 3.33, the current P/B ratio is approximately 430.70% higher. Relative to its 5-year average P/B ratio of 2.87, the current P/B ratio is about 514.42% higher. Praxis Precision Medicines Inc (PRAX) has a Forward Free Cash Flow (FCF) yield of approximately -3.20%. Compared to its 3-year average FCF yield of -55.81%, the current FCF yield is approximately -94.27% lower. Relative to its 5-year average FCF yield of -61.97%, the current FCF yield is about -94.84% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for PRAX competitors is 1579.18, providing a benchmark for relative valuation. Praxis Precision Medicines Inc Corp (PRAX.O) exhibits a P/S ratio of 8230.35, which is 421.18% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of PRAX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of PRAX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is PRAX currently overvalued or undervalued?

Praxis Precision Medicines Inc (PRAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8230.35 is considered Overvalued compared with the five-year average of -4.21. The fair price of Praxis Precision Medicines Inc (PRAX) is between 35.02 to 173.40 according to relative valuation method. Compared to the current price of 309.91 USD, Praxis Precision Medicines Inc is Overvalued By 78.72%.

What is Praxis Precision Medicines Inc (PRAX) fair value?

PRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Praxis Precision Medicines Inc (PRAX) is between 35.02 to 173.40 according to relative valuation method.

How does PRAX's valuation metrics compare to the industry average?

The average P/S ratio for PRAX's competitors is 1579.18, providing a benchmark for relative valuation. Praxis Precision Medicines Inc Corp (PRAX) exhibits a P/S ratio of 8230.35, which is 421.18% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.

What is the current P/B ratio for Praxis Precision Medicines Inc (PRAX) as of Mar 11 2026?

As of Mar 11 2026, Praxis Precision Medicines Inc (PRAX) has a P/B ratio of 17.65. This indicates that the market values PRAX at 17.65 times its book value.

What is the current FCF Yield for Praxis Precision Medicines Inc (PRAX) as of Mar 11 2026?

As of Mar 11 2026, Praxis Precision Medicines Inc (PRAX) has a FCF Yield of -3.20%. This means that for every dollar of Praxis Precision Medicines Inc's market capitalization, the company generates -3.20 cents in free cash flow.

What is the current Forward P/E ratio for Praxis Precision Medicines Inc (PRAX) as of Mar 11 2026?

As of Mar 11 2026, Praxis Precision Medicines Inc (PRAX) has a Forward P/E ratio of -21.34. This means the market is willing to pay $-21.34 for every dollar of Praxis Precision Medicines Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Praxis Precision Medicines Inc (PRAX) as of Mar 11 2026?

As of Mar 11 2026, Praxis Precision Medicines Inc (PRAX) has a Forward P/S ratio of 8230.35. This means the market is valuing PRAX at $8230.35 for every dollar of expected revenue over the next 12 months.

PRAX Valuation